The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Open accessAbstract
Purpose: Biomarkers can add substantial value to current medical practice by providing an integrated approach to prediction using the genetic makeup of the tumor and the genotype of the patient to guide patient-specific treatment selection. We discuss and evaluate various clinical trial designs for the validation of biomarker-guided therapy. Methods: Designs for predictive marker validation are broadly classified as retrospective (ie, using data from previously well-conducted randomized controlled trials [RCTs]) versus prospective (enrichment, unselected, hybrid, or adaptive analysis). We discuss the salient features of each design in the context of real trials. Results: Well-designed retrospective analysis from well-conducted prospective RCTs can bring forward effective treatments to marker-defined subgroups of patients in a timely manner (eg, KRAS and colorectal cancer). Enrichment designs are appropriate when preliminary evidence suggest that patients with or without that marker profile do not benefit from the treatments in question; however, this may sometimes leave questions unanswered (eg, trastuzumab and breast cancer). An unselected design is optimal where preliminary evidence regarding treatment benefit and assay reproducibility is uncertain (eg, epidermal growth factor receptor and lung cancer). Hybrid designs are appropriate when preliminary evidence demonstrate the efficacy of certain treatments for a marker-defined subgroup, making it unethical to randomly assign patients with that marker status to other treatments (eg, multigene assay and breast cancer). Adaptive analysis designs allow for prespecified marker-defined subgroup analyses of data from an RCT. Conclusion: The implementation of these design strategies will lead to a more rapid clinical validation of biomarker-guided therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cited by
Hutchins, G., Southward, K., Handley, K., Magill, L., Beaumont, C., Stahlschmidt, J., Richman, S., Chambers, P., Seymour, M., Kerr, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1366 · Cited by 681
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer
Rusling, J. F., Kumar, C. V., Gutkind, J. S., & Patel, V. (2010) · The Analyst · doi:10.1039/c0an00204f · Cited by 552
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Self-citationGray, R. G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F. L., Beaumont, C., Clark-Langone, K. M., Yoshizawa, C. N., Lee, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8732 · Cited by 380
Randomized Clinical Trials With Biomarkers: Design Issues
Freidlin, B., McShane, L. M., & Korn, E. L. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp477 · Cited by 369
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
Translating cancer research into targeted therapeutics
de Bono, J. S., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 335
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Self-citationPatient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 282
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 278
Biomarkers for Aging Identified in Cross-sectional Studies Tend to Be Non-causative
Nelson, P. G., Promislow, D. E. L., & Masel, J. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz174 · Cited by 65
Bienkowski, M., Berghoff, A. S., Marosi, C., Wöhrer, A., Heinzl, H., Hainfellner, J. A., & Preusser, M. (2015) · Clinical Neuropathology · doi:10.5414/np300904 · Cited by 57
“Various specific prospective study designs for predictive biomarker studies have been suggested [37, 38, 39, 40, 41, 42, 43]; some with specific emphasis on determining predictive cut-points for continuously measured biomarkers [44, 45, 46].”
Background
Metadata
- Authors
- Mandrekar, S. J., & Sargent, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-20
- Volume
- 27
- Issue
- 24
- Pages
- 4027-4034
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108710215
- Cited by
- 404
- References
- 47
- FWCI
- 31.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.